(S)-3-methyl-5-phenyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one | 62492-80-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 英文名称: (S)-3-methyl-5-phenyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one
• 英文别名: (3S)-3-Methyl-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one；(3S)-3-methyl-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one
• CAS: 62492-80-2
• 化学式: C₁₆H₁₄N₂O
• 分子量: 250.3
• InChiKey: QFCQGJLUYWNOAC-NSHDSACASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  41.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (S)-3-methyl-5-phenyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one 在 硫酸 、 溴 、 溶剂黄146 、 sodium hydroxide 作用下， 以 水 为溶剂， 以81%的产率得到SH-I-030
  参考文献：
  名称：

  Stereospecific anxiolytic and anticonvulsant agents with reduced muscle-relaxant, sedative-hypnotic and ataxic effects

  摘要：

  本发明提供了使用立体特异性苯二氮卓类衍生物、它们的盐和前药治疗焦虑症或癫痫发作障碍的组合物和方法，该方法具有减少酒精渴望的副作用，同时减少酒精成瘾者的镇静、催眠、肌肉松弛和共济失调副作用。本发明还提供了用于治疗焦虑症和癫痫发作障碍的药物组合物，包括具有化学结构由任何一种I-XXI式表示的化合物、前药或盐，以及一种药学上可接受的载体。

  公开号：

  US20060003995A1
• 作为产物：
  描述：

  (2S)-2-amino-N-(2-benzoylphenyl)propanamide 在 溶剂黄146 作用下， 以 二氯甲烷 为溶剂， 生成 (S)-3-methyl-5-phenyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one
  参考文献：
  名称：

  Novel 1,4-benzodiazepine derivatives with antiproliferative properties on tumor cell lines

  摘要：

  Novel 1,4-benzodiazepine compounds were synthesized and evaluated for their ability to inhibit the proliferation of tumor cells. Some compounds revealed activities in the micromolar range and were more efficient than reference compound Ro 5-4864. Preliminary SAR helped to identify critical motifs for antiproliferative activity and led to the discovery of a compound selective for a melanoma cell line, known for its resistance to chemotherapy. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.02.016

文献信息

• Design and synthesis of benzodiazepine analogs as isoform-selective human lysine deacetylase inhibitors
  作者：D. Rajasekhar Reddy、Flavio Ballante、Nancy J. Zhou、Garland R. Marshall

  DOI：10.1016/j.ejmech.2016.12.032

  日期：2017.2

  comprehensive investigation was performed to identify new benzodiazepine (BZD) derivatives as potent and selective human lysine deacetylase inhibitors (hKDACis). A total of 108 BZD compounds were designed, synthesized and from that 104 compounds were biologically evaluated against human lysine deacetylases (hKDACs) 1, 3 and 8 (class I) and 6 (class IIb). The most active compounds showed mid-nanomolar potencies

  进行了全面的调查，以确定新的苯二氮卓（BZD）衍生物作为有效的和选择性的人赖氨酸脱乙酰基酶抑制剂（hKDACis）。总共设计，合成了108种BZD化合物，并从这104种化合物中分别针对人赖氨酸脱乙酰基酶（hKDAC）1、3和8（I类）和6（IIb类）进行了生物学评估。活性最高的化合物对hKDACs 1、3和6表现出中等纳摩尔效价，对hKDAC8的微摩尔活性，而一种有前途的化合物（6q）显示出在不同酶同工型中对hKDAC3的选择性。生成了hKDAC6同源性模型，该模型通过分子动力学模拟进行了改进，并进行了分子对接研究，以使主要的配体-残基相互作用合理化，并定义了结构-活性-关系。实验结果证实了在追求hKDAC同工型选择性抑制时，苯并二氮杂moiety部分作为封端基是有用的，这表明在设计新的hKDACis时可以继续使用。
• Enantioselective Synthesis of Diversely Substituted Quaternary 1,4-Benzodiazepin-2-ones and 1,4-Benzodiazepine-2,5-diones
  作者：Paul R. Carlier、Hongwu Zhao、Stephanie L. MacQuarrie-Hunter、Joseph C. DeGuzman、Danny C. Hsu

  DOI：10.1021/ja0640142

  日期：2006.11.1

  Benzodiazepines are privileged scaffolds in medicinal chemistry, but enantiopure examples containing quaternary stereogenic centers are extremely rare. We demonstrate that installation of the di(p-anisyl)methyl (DAM) group at N1 of 1,4-benzodiazepin-2-ones and 1,4-benzodiazepine-2,5-diones derived from enantiopure proteinogenic amino acids allows retentive replacement of the C3-proton via a deprotonation/trapping

  苯二氮卓类药物是药物化学中的特殊支架，但含有四元立体中心的对映体纯的例子极为罕见。我们证明了在源自对映体纯蛋白氨基酸的 1,4-苯二氮卓-2-酮和 1,4-苯二氮卓-2,5-二酮的 N1 处安装二（对茴香基）甲基 (DAM) 基团允许保留替换C3 质子通过去质子化/捕获协议。多种碳和氮亲电子试剂在该反应中发挥良好作用，为相应的季苯二氮卓类化合物提供了出色的对映选择性。一对非对映体 1,4-苯二氮卓-2,5-二酮的去质子化/捕获实验为构象手性在这些对映选择性反应中的关键作用提供了证据。DAM 基团的酸性去除速度快且产率高，并且可以在 N-Boc 吲哚存在下选择性地进行。因此，现在可以完成具有不同 N1 功能的季苯二氮卓类化合物的合成。
• Stereospecific anxiolytic and anticonvulsant agents with reduced muscle-relaxant, sedative-hypnotic and ataxic effects
  申请人：Cook M. James

  公开号：US20060003995A1

  公开（公告）日：2006-01-05

  The present invention provides compositions and methods of using stereospecific benzodiazepine derivatives, their salts and prodrugs for the treatment of anxiolytic or convulsant disorders having the side effects of reduced alcohol craving in human alcoholics and a concomitant reduced sedative, hypnotic, muscle relaxant and ataxic side-effects. The invention further provides pharmaceutical compositions for treatment of anxiolytic and convulsant disorders in subjects in need thereof, comprising a compound, prodrug or a salt having a chemical structure represented by any one of Formula I-XXI and a pharmaceutically-acceptable carrier.

  本发明提供了使用立体特异性苯二氮卓类衍生物、它们的盐和前药治疗焦虑症或癫痫发作障碍的组合物和方法，该方法具有减少酒精渴望的副作用，同时减少酒精成瘾者的镇静、催眠、肌肉松弛和共济失调副作用。本发明还提供了用于治疗焦虑症和癫痫发作障碍的药物组合物，包括具有化学结构由任何一种I-XXI式表示的化合物、前药或盐，以及一种药学上可接受的载体。
• [EN] STEREOSPECIFIC ANXIOLYTIC AND ANTICONVULSANT AGENTS WITH REDUCED MUSCLE-RELAXANT, SEDATIVE-HYPNOTIC AND ATAXIC EFFECTS<br/>[FR] AGENTS ANXIOLYTIQUES ET ANTICONVULSIFS STEREOSPECIFIQUES PRESENTANT DES EFFETS MYORELAXANTS, SEDATIFS-HYPNOTIQUES ET ATAXIQUES REDUITS
  申请人：WISYS TECHNOLOGY FOUND INC

  公开号：WO2006004945A1

  公开（公告）日：2006-01-12

  The present invention provides compositions and methods of using stereospecific benzodiazepine derivatives, their salts and prodrugs for the treatment of anxiolytic or convulsant disorders having the side effects of reduced alcohol craving in human alcoholics and a concomitant reduced sedative, hypnotic, muscle relaxant and ataxic side-effects. The invention further provides pharmaceutical compositions for treatment of anxiolytic and convulsant disorders in subjects in need thereof, comprising a compound, prodrug or a salt having a chemical structure represented by any one of Formula I-XXI and a pharmaceutically-acceptable carrier.

  本发明提供了使用立体特异性苯二氮平衍生物、它们的盐和前药治疗焦虑或惊厥性疾病的组合物和方法，其副作用为减少酒精成瘾，同时减少镇静、催眠、肌肉松弛和共济失调的副作用。本发明还提供了制药组合物，用于治疗需要的患有焦虑和惊厥性疾病的受试者，包括具有化学结构的化合物、前药或盐，该化学结构由公式I-XXI中的任何一个表示，并且具有药学上可接受的载体。
• STEREOSPECIFIC ANXIOLYTIC AND ANTICONVULSANT AGENTS WITH REDUCED MUSCLE-RELAXANT, SEDATIVE-HYPNOTIC AND ATAXIC EFFECTS
  申请人：Cook James M.

  公开号：US20100004226A1

  公开（公告）日：2010-01-07

  The present invention provides compositions and methods of using stereospecific benzodiazepine derivatives, their salts and prodrugs for the treatment of anxiolytic or convulsant disorders having the side effects of reduced alcohol craving in human alcoholics and a concomitant reduced sedative, hypnotic, muscle relaxant and ataxic side-effects. The invention further provides pharmaceutical compositions for treatment of anxiolytic and convulsant disorders in subjects in need thereof, comprising a compound, prodrug or a salt having a chemical structure represented by any one of Formula I-IV, VI-XI, XV-XVIII and XX-XXI and a pharmaceutically-acceptable carrier.

  本发明提供了立体特异性苯二氮平衍生物、其盐和前药的组合物及使用方法，用于治疗焦虑或惊厥性疾病，在人类酗酒者中具有减少酒精渴望的副作用，以及同时减少镇静、催眠、肌肉松弛和共济失调的副作用。本发明进一步提供了用于治疗需要该类治疗的焦虑和惊厥性疾病患者的药物组合物，包括具有化学结构的化合物、前药或盐Formula I-IV、VI-XI、XV-XVIII和XX-XXI中的任意一个，并且是药学可接受的载体。